

ADR research

SymBio Pharmaceuticals

With experience comes confidence

Three steps forward, one step back. With the December filing of three supplemental NDAs for Treakisym, SymBio is demonstrating it is willing to move ahead with its strategic plans despite Astellas's decision to withdraw its long-delayed EU application for Treakisym in first-line iNHL. Separately, Baxalta announced on 3 March that it would discontinue its development and licensing agreement with Onconova for rigosertib as of August. Onconova is in discussions with Baxalta; however, it is not clear whether Baxalta will help Onconova obtain alternate funding to complete the trial. Issues with SymBio's partners may have an impact on the timeframes for both rigosertib and the Treakisym label expansion approvals.

Year end	Revenue (\$m)	PTP (\$m)	EPADR (\$)	DPADR (\$)	P/E (x)	Gross Yield (%)
12/14	16.2	(9.2)	(0.30)	0.0	N/A	N/A
12/15	16.0	(21.8)	(0.67)	0.0	N/A	N/A
12/16e	16.1	(22.6)	(0.70)	0.0	N/A	N/A
12/17e	18.9	(27.5)	(0.85)	0.0	N/A	N/A

Note: Converted at ¥121/US\$. Dividend yield excludes withholding tax. Investors should consult their tax advisor regarding the application of any domestic and foreign tax laws.

Files label expansion sNDAs for Treakisym

In December, SymBio filed three supplemental NDAs in Japan for Treakisym to treat first-line iNHL/MCL, CLL and for a 25mg vial dosage strength. SymBio has generally waited to file for approval in Japan once an indication has been received from both US and EU regulators. However, Astellas withdrew its application for first-line NHL/MCL approval in the EU in January 2016 following numerous delays in the approval, which was initially expected in late 2014/early 2015. SymBio's decision to progress in Japan independently of Astellas's decision highlights SymBio's confidence in approval for these new indications and perhaps substantiates Astellas's assertion that it withdrew due to technicalities in the EU approval process. Upside sales from additional indications for Treakisym account for 12% of our risk-adjusted valuation for SymBio.

Potential funding setback for rigosertib

On 3 March, Baxalta announced it would no longer seek to develop and license rigosertib with Onconova, citing changes in its development priorities. Onconova recently began to enrol patients in its Phase III INSPIRE trial and SymBio had agreed to contribute 25-30 patients to the trial along with the related costs. If Onconova is unable to negotiate funding to complete the trial, we believe this would reduce the likelihood that SymBio will be able to get rigosertib approved in Japan. We are reducing our risk-adjusted probability of success for IV rigosertib from 60% to 50% as a result of this announcement.

Valuation: Risk-adjusted NPV of \$4.91/share

Our rNPV includes ¥4,261m (\$35m) cash, Treakisym, IONSYS and our lowered possibility for IV rigosertib. SymBio will require funding during 2017 and we assume a total funding requirement of ¥6.6bn from 2017-18.

Business update

Pharma & biotech

23 March 2016

32.4m

OTC

Price \$1.81

Market cap \$59m

ADR/Ord conversion ratio 1:1

Net cash (\$m) at December 2015 35.2

ADR Code SYMQY

Underlying exchange Tokyo
Depository BNY

Business description

SymBio Pharmaceuticals is a Japanese specialty pharma company with a focus on oncology, haematology and pain management. Treakisym was in-licensed from Astellas in 2005. Rigosertib was in-licensed from Onconova and IONSYS was in-licensed from The Medicines Company.

Next events

ADRs in issue

ADR exchange

March results May 2016
IONSYS Phase III trial start H216

Analysts

Beth Senko +1 646 653 7026 Christian Glennie +44 (0)20 3077 5727

healthcare@edisongroup.com

Edison profile page

SymBio Pharmaceuticals is a research client of Edison Investment Research Limited



Update: Pushing ahead as partners face challenges

SymBio was established in 2005 with the aim of becoming a specialty pharma company focused on addressing high unmet medical needs in Asia-Pacific. SymBio's primary strategy is to in-license assets with proof-of-concept (Phase II) data for development and commercialization in Asia-Pacific, removing the need for investment in early-stage R&D. As the company grows, management has indicated it may consider assets that are in earlier stages of development, particularly if it is able to acquire global marketing rights. While SymBio currently out-licenses sales and distribution of its lead asset Treakisym, the company plans to market rigosertib, IONSYS and any new in-licensed product by building out its own commercial infrastructure. In-licensing additional assets will be central to driving future operating leverage.

SymBio was very active in the last quarter of 2015. After contending with regulatory and clinical development delays for new indications for Treakisym and initial approval for rigosertib and a heated market for identifying attractive in-licensing candidates for most of 2015, SymBio in-licensed a new product (IONSYS), filed three supplemental NDAs for Treakisym in iNHL/MCL, CLL along with a new 25mg vial dose, and began recruiting patients for the new global Phase III INSPIRE trial for rigosertib.

After SymBio filed for Treakisym approval in first-line iNHL/MCL, in January, Astellas withdrew its application for EU approval of Treakisym for this indication. EU approval was originally expected in late 2014/early 2015, and was delayed numerous times as the BfArM (the German drug approval agency) requested additional data. However, Astellas may refile in 2017 when data from a study comparing Treakisym to R-CHOP is available. SymBio's decision to progress in Japan independently of Astellas's decision highlights SymBio's confidence in approval for these new indications and perhaps substantiates Astellas's assertion that it withdrew due to technicalities in the EU approval process.

On 3 March, Baxalta announced it would no longer seek to develop and license rigosertib with Onconova as of 31 August, citing changes in its development priorities. Onconova recently began to enrol patients in its Phase III INSPIRE trial and SymBio had agreed to contribute 25-30 patients to the trial along with the related patient costs. Baxalta is expected to fund its portion of trial expenses through to the end of August and Onconova is in discussions with Baxalta about funding required to complete the trial. At this point, it is too soon to know if Baxalta will help Onconova obtain additional funding or help identify a new development partner for rigosertib. If Onconova is unable to negotiate funding to complete the trial, we believe this would reduce the likelihood that SymBio will be able to get rigosertib approved in Japan.

With the recent pullback in biotech valuations, and several years of laying the groundwork as a strong in-licensing partner for Asia-Pacific, we believe that SymBio is seeing greater potential deal flow, which should lead to more licensing opportunities. Management has also expressed an interest in evaluating potential transactions from an earlier stage. In February, SymBio announced it will begin a joint research and development program with Teikyo Heisei University for an anticancer drug using the TTR1 nano-agonist molecule. SymBio will invest c ¥10m (US\$0.1m) for 2016 in this venture and will consider further investment based on research results. While we expect the company to take the same cautious approach to earlier-stage candidates as it has with its other transactions, we believe it will help provide visibility on sales growth beyond the 2020-23 timeframe.



Pipeline update

Treakisym

SymBio acquired the rights to develop and commercialize Treakisym from Astellas in Japan (2005) and subsequently in China/Hong Kong, Korea, Taiwan and Singapore (April 2007). In 2008, SymBio out-licensed marketing of Treakisym to select commercial partners as a way to generate cash to support further development opportunities. The agreements call for royalties and milestones, but precise deal terms have not been disclosed. We estimate that SymBio earns an average net margin of around 10-12% on top-line reported Treakisym sales in Asia-Pacific.

Treakisym is approved for r/r iNHL/MCL patients in Japan. We estimate SymBio (through its partnership with Eisai) had Treakisym sales of ¥4,270m (\$35m) in 2015. This number is expected to grow 5-6% pa until 2020 when the patent expires.

First-line iNHL/MCL: SymBio completed pivotal development in first-line iNHL in 2014 and SymBio filed its sNDA for this indication at the end of December. This filing was delayed through most of 2014 and 2015 as SymBio waited for the treatment to be approved in Europe. Astellas filed for approval in Europe for first-line iNHL with data from the StiL study demonstrating a PFS (progression free survival) of 69.5 months for patients treated with BR (bendamustine + rituximab), significantly longer than 31.2 months for R-CHOP (rituximab/Rituxan in combination with CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, and prednisone). The BRIGHT study demonstrated that BR was non-inferior to R-CHOP in terms of complete response rate (31% vs 25%, respectively, p=0.0225) However, the German drug approval authority, BfArM, kept delaying approval by asking for additional data and analyses. Astellas withdrew its application at the end of January; however, SymBio opted to move ahead with its approval application in Japan based on Phase II data in Japan and Phase III data in the EU. It is possible that Astellas will refile for EU approval in 2017 when new data comparing Treakisym to R-CHOP therapy is released.

Approval for this indication could materially expand Treakisym's potential, given this is a patient market of 7,100, which is c 50% larger than the currently approved r/r iNHL indication with an estimated patient population of 4,700. Furthermore, there are generally more treatment cycles per patient in first-line iNHL (six cycles in first-line iNHL vs four to five cycles in r/r iNHL).

Treakisym in CLL: SymBio completed its pivotal Phase II trial for CLL in 2015 and filed for approval in Japan for this indication at the end of December. This indication is already approved in both the US and Europe, so we believe this indication has a high chance to also gain approval in Japan.

First-line iNHL and CLL could more than double current sales: Together, we believe that sales in both first-line iNHL and CLL could reach ¥8,151m by 2020 if Treakisym can achieve a similar 50% market share as in r/r iNHL.

Treakisym in r/r aggressive NHL: SymBio has also completed development in r/r aggressive NHL (a patient population of 6,700 in Japan) in 2012. However, filing has been delayed owing to discussions with regulators, which are still ongoing at the time of publication. It is possible that approval will only be granted subject to conducting an additional comparative trial. However, we think it is unlikely that SymBio will invest in further development in r/r aggressive NHL owing to the expiry of market exclusivity in 2020. Hence we do not include a contribution from this indication in our valuation. If this indication can be approved, it could add ¥3,000-5,000m in sales.

Rigosertib

SymBio in-licensed rigosertib (IV and oral formulations, Japan and Korean rights) from Onconova in 2011 for myelodysplastic syndromes (MDS), a rare blood cancer; it is partnered with



Baxalta(formerly the bioscience business of Baxter International) in Europe for higher-risk myelodysplastic syndromes (HR-MDS).

Following discussions between Onconova and regulatory agencies, development of rigosertib was moving forward with the start of the new pivotal Phase III INSPIRE trial. The pivotal trial, designated 04-30 or 'INSPIRE', will enrol HR-MDS patients less than 80 years of age who had progressed on, or failed to respond to, previous treatment with hypomethylating agents (HMA) within the first nine months of initiating HMA treatment, and had their last dose of HMA therapy within six months prior to enrolment in the trial. This is the patient subset where rigosertib demonstrated a significant benefit in the Phase III ONTIME trial, Onconova's first Phase III trial for rigosertib (which failed to meet its primary endpoint but demonstrated meaningful results for a subset of patients). The primary endpoint of this new Phase III INSPIRE trial will be overall survival, and an interim analysis is anticipated. This randomized trial of approximately 225 patients will be conducted at about 100 sites globally and Onconova enrolled its first patient in early December. SymBio committed to contribute 25-30 patients and costs related to those patients; interim results are expected in H117.

Onconova signed a \$16.5m financing agreement with Lincoln Park Capital in late 2015 to help with clinical trial costs. Per a development and licensing agreement Onconova signed with Baxalta, which grants Baxalta commercialization rights to rigosertib in the EU and other countries in Europe, Baxalta would have paid for half the costs of the Phase III INSPIRE trial up to a specified cap. However, on 3 March, Baxalta announced it would discontinue its development and licensing agreement for rigosertib and INSPIRE after 31 August. However, Baxalta is obligated to fund its portion of trial costs until the end of August. Onconova is in discussions with Baxalta regarding the amount of financial support needed to complete the INSPIRE trial; however it is not clear whether Baxalta will help Onconova obtain alternate funding to complete the trial or whether it will identify another partner. SymBio is currently reviewing its options as a result of this disappointing news and we await further information.

On the oral formulation side, as a result of Onconova's earlier trials, the safety of the oral formulation of rigosertib for monotherapy was confirmed, and SymBio started its domestic Phase I clinical trial of the oral formulation of rigosertib in combination with azacitidine in December 2015. We assume SymBio completes this trial in the first half of 2016 and its participation in the global Phase III clinical trial to be conducted by Onconova is under consideration.

Onconova will most likely require additional cash to pursue future trials; this could delay initiation of SymBio's future trials and could therefore affect launch timelines.

IONSYS

In October 2015, SymBio acquired an exclusive licence in Japan to develop and market IONSYS, a patient controlled fentanyl iontophoretic transdermal system for the short-term management of acute postoperative pain.

We believe SymBio views IONSYS as a market-changing product due to its credit-card sized, needle-free design that does not require the patient to be tethered to an IV line and other equipment. We also believe IONSYS will be fairly straightforward to commercialize and it will help reinforce SymBio's presence as a strong development and commercial partner for Asia-Pacific, in addition to diversifying risk.

Our preliminary peak sales number of ¥6,500m (\$55m) for IONSYS in Japan is based on the rate of post-surgical PCA use in the US (1.4 million patients in a US population of 311 million). This is discounted to reflect studies from the <u>European Society of Medical Oncologists (ESMO)</u> suggesting that postsurgical opioid use is much lower in Japan than other developed countries. While the company has not announced definitive plans, we expect that SymBio will seek to market IONSYS through its own salesforce.



SymBio is finishing the regulatory filings that will enable it to obtain opioids in Japan to conduct clinical tests for IONSYS and expects to begin the Phase III trial in Q316. If approved, SymBio could launch IONSYS at some point in 2019.

Sensitivities

SymBio is subject to the usual drug development risks, including clinical development delays or failures, regulatory risks, competitor successes, partnering setbacks, financing and commercial risks. The main sensitivities for SymBio include:

- Expansion of Treakisym to additional indications, including first-line iNHL to drive growth; and SymBio's ability to gain approval in Japan before it is approved in the EU.
- Rigosertib success or failure, which will hinge largely on its recently launched Phase III
 INSPIRE global trial and Onconova's ability to secure additional funding for the trial to replace
 Baxalta's share of the development costs.
- SymBio's ability to execute future in-licensing deals, especially to leverage future commercial operations.

SymBio is reliant on in-licensing assets to fill its pipeline and this will become even more important for leveraging future commercial operations. To date, SymBio has executed four deals for products with clinical proof-of-concept data, although development for one of these has been terminated following a lack of efficacy. We believe the CEO's network is crucial to securing future deals, although we have limited visibility on the potential terms and timing of any such agreements.

Valuation

We value SymBio at ¥19,227m (\$159m) or \$4.91/share, based on a risk-adjusted NPV analysis. We have rolled our valuation model forward to reflect the start to a new calendar year. Our rNPV includes ¥4,261m (\$35m) net cash, Treakisym, rigosertib and IONSYS. Our net cash numbers are based on Q415 results.

Exhibit 1: SymBio rNPV valuation										
Product	Indication	Launch	Peak sales (\$m)	Value (\$m)	Probability	rNPV (\$m)	NPV/ADR (\$/ADR)			
Treakisym (existing sales)	r/r iNHL/MCL	2010	55	22.2	100%	22.2	0.7			
Treakisym (label expansion sales)	Frontline iNHL/MCL; CLL	late 2016	80	20.8	90%	18.7	0.6			
Ribosertib (IV)	r/r high risk MDS	2019	30	33.6	50%	15.1	0.5			
Ribosertib (oral)	Low risk MDS	2019	70	76.2	25%	14.5	0.4			
IONSYS	Opioid	2019	55	56.0	95%	53.2	1.6			
Net Cash				35.2	100%	35.2	1.1			
Valuation				244.0		158.9	4.91			
Source: Edison Investment Research. Note: Peak sales are rounded to nearest \$5m.										

We use a 10% discount rate for approved products and 12.5% elsewhere. Our valuation includes both Treakisym and rigosertib. For Treakisym we include current sales and upside from sales in first-line iNHL and CLL; we do not include any potential in r/r aggressive NHL. Our Treakisym valuation assumes that SymBio earns an average net margin of 10-12% on top-line reported Treakisym sales. Our rigosertib forecasts include future R&D spend in addition to the cost of building out a sales infrastructure; we do not include any potential in indications beyond those currently under development, which could include solid tumours, AML and broader use in MDS in

combination with other agents. Our IONSYS forecasts are based on our preliminary estimates for



royalties paid to The Medicines Company at 15%, along with potential development and sales milestones, R&D and S&M costs.

We have maintained our 90% probability for Treakisym label expansion sales and have maintained our peak sales estimate of c \$80m (¥8bn), albeit with a more backend-loaded sales ramp up. We have maintained our launch date of Q416 based on SymBio's late December filing for approval in Japan, but also to reflect what may be a longer approval time as SymBio will no longer be able to include information on EU approval as Astellas recently withdrew its EU application after numerous approval delays.

In December, we raised our probability on IV rigosertib from 50% to 60% to reflect Onconova's successful initiation of a new pivotal Phase III trial in HR-MDS as well as its recent \$16.5m financing to support the testing. However, with Baxalta's recent announcement it would discontinue its participation, we have lowered our probability on IV rigosertib back to 50%. Our 25% probability on oral rigosertib is unchanged.

Financials

SymBio reported cash of ¥4,261m (\$35m) at end-December 2015, which includes current investments with more than three months' maturity; we do not exclude these longer-term investments from the cash in our valuation. We believe cash should be sufficient to fund current operations into early- to mid-2017, unless the company signs additional licensing agreements during 2016. We assume additional funds will be needed at this point, both to start building out a sales and marketing infrastructure ahead of the potential launches of IONSYS and rigosertib in 2019, and for milestones that could become due to partner Onconova if rigosertib is approved in both the US and Japan. Our model uses illustrative debt funding of c \$55m (¥6.6bn) from 2017-18.

2015 results on target: for 2015, SymBio reported results generally in line with guidance as well as our estimates. Revenue totalled \$16m (¥1,933m), approximately in line with our estimate of \$16.4m (¥1,951m) and slightly ahead of guidance of ¥1,870m. The primary difference stemmed from the timing of a Treakisym shipment to South Korea, which booked at the end of 2014, instead of early 2015. Gross profit totalled \$4.8m (¥583m), below our estimate of \$5.1m (¥613m). SymBio posted R&D expenses (excluding SG&A) of \$16.8m (¥2,035m), compared with our \$16.3m (¥1,946m) estimate and SymBio's guidance of ¥1,866m. Operating expenses (which include R&D and SG&A) were \$25.9m (¥3,134m), compared with our estimate of \$25.6m (¥3,108m) and guidance of ¥2,999m.

Fine-tuning 2016 estimates: SymBio's revised guidance for 2016 falls largely in the mid-point of the guidance issued a year ago. As SymBio is going ahead with its Treakisym label expansion application without EU approval, we are further reducing our label expansion sales in 2016 as well as a related delay in spending for marketing and milestone payments. Hence, our revenues in 2016 are towards the bottom end of SymBio's outlook. Our operating, ordinary and net loss forecasts in 2016 are above SymBio's outlook as we do not include unknown or uncertain future milestone payments for future out-licensing activities (which we believe are included in SymBio's outlook). We believe these elements explain the majority of the difference between the company's last published guidance and our recently updated estimates. Our revised forecasts for 2016 are broadly in line with SymBio's 2016 financial guidance, summarised in Exhibit 2.



Exhibit 2: SymBio guidance for 2016 and Edison estimates									
	SymBio guidance	Edison e	Difference (guidance						
		Previous	Current	vs estimates)					
Revenue	¥2,339m	¥2,140m	¥1,951m	¥388m					
Operating loss	¥2,778m	¥2,086m	¥2,733m	¥45m					
Ordinary loss	¥2,811m	¥2,076m	¥2,724m	¥87m					
Net loss	¥2,815m	¥2,080m	¥2,728m	¥87m					

Source: SymBio Pharmaceuticals reports and Edison Investment Research estimates

More conservative guidance for 2017; initial guidance for 2018: SymBio released its mid-range financial guidance for 2017 and 2018 on 10 February. Compared with its previous mid-range guidance released in February 2015, SymBio lowered the top end of its sales range for 2017 and became less optimistic on operating losses. In our view, the more conservative expectations are reasonable given delays for Treakisym label expansion and incremental R&D spend for IONSYS since the last mid-range guidance update. Our lowered sales expectations reflect a more modest ramp up of Treakisym label expansion sales vs our previous revenue estimate.

Exhibit 3: SymBio guidance for 2017 and Edison estimates										
	SymBio guidance,	10 February 2016	Edison e	stimates	Differ	ence				
	Low	High	Previous	Current	Low	High				
Revenue	¥2,188m	¥2,604m	¥2,829m	¥2,290m	(¥102m)	¥314m				
Operating loss	¥3,521m	¥3,379m	¥2,563m	¥3,316m	¥205m	¥63m				
Ordinary loss	¥3,554m	¥3,412m	¥2,563m	¥3,316m	¥238m	¥96m				
Net loss	¥3.558m	¥3.416m	¥2.566m	¥3.320m	¥238m	¥96m				

Source: SymBio Pharmaceuticals reports and Edison Investment Research estimates

	SymBio guidance,	10 February 2016	Edison	Difference		
	Low	High	estimates	Low	High	
Revenue	¥2,298m	¥2,974m	¥2,897m	¥599m	¥77m	
Operating loss	¥3,778m	¥3,526m	¥3,793m	(¥15m)	(¥267m)	
Ordinary loss	¥3,811m	¥3,559m	¥3,793m	(¥18m)	(¥234m)	
Net loss	¥3,815m	¥3,563m	¥3,797m	(¥18m)	(¥234m)	

Source: SymBio Pharmaceuticals reports and Edison Investment Research estimates



December JPN GAMP	US\$:JPY	\$'000s	2013	2014	2015	2016e	2017e	20186
Revenue 12.662 16.157 15.977 16.125 18.909 23.9 23.0 20.0 col for Sales (10.034) (11.895) (11.195) (10.196) (13.252) (10.855) (10.034) (11.895) (11.195) (11.916) (13.252) (10.855) (10.034) (13.252) (10.855) (10.034) (13.252) (10.855) (10.034) (13.252	December		JPN GAAP	JPN GAAF				
Cost of Sales	PROFIT & LOSS							
Gross Porfil Research and development (R) (R) (0.398) (1.0186) (1.75) (2.529) (5.603) (7.0) Research and development (18, 10.399) (1.0816) (1.75) (1.780) (2.552) (2.233) (3.10) Operating Porfit (feefore amort, and except.) (13.343) (9.427) (2.1826) (2.25.72) (2.233) (3.10) Operating Porfit (feefore amort, and except.) (13.343) (9.427) (2.1826) (2.25.72) (2.233) (3.10) Operating Porfit (13.343) (9.427) (2.1856) (2.259) (2.7487) (2.7487) (3.10) Operating Porfit (13.343) (9.396) (2.1866) (2.259) (2.7487) (3.142) Nel Interest (18.325) (9.396) (2.1866) (2.259) (2.7408) (3.134) Nel Interest (18.325) (9.396) (2.1866) (2.259) (2.7408) (3.134) Nel Interest (18.325) (9.191) (2.171) (2.2513) (2.7408) (3.134) Nel Interest (18.325) (9.191) (2.171) (2.2513) (2.7408) (3.134) Fre-tax Profit (reported) (13.266) (9.224) (2.1816) (2.2590) (2.7408) (3.134) Tay (19.325) (9.191) (2.1721) (2.2513) (2.7408) (2.1804) Tay (19.325) (9.191) (2.1721) (2.2513) (2.1721) (2.2513) (2.1721) (2.1721) (2.1721) (2.1721) (2.1721	Revenue		12,662	16,157	15,977	16,125	18,929	23,945
Research and development (3,701)	Cost of Sales		(10,034)	(11,805)	(11,159)	(10,916)	(13,326)	(16,857)
Commonstrated Commonstrate	Gross Profit		2,628	4,352	4,818	5,209	5,603	7,088
Commission Com	Research and development		(8,701)	(6,398)	(16,816)	(17,579)	(17,880)	(22,201)
nitangplike Amortization 25 48 77 78 79 10 0 0 10 15 17 0 0 10 0 0 0 0 0 0 10 0 0 0 0 0 10 0 0 0	EBITDA		(13,301)	(9,372)	(21,826)	(22,522)	(27,233)	(31,037)
Exceptionals	Operating Profit (before amort. and except.)		(13,343)	(9,429)	(21,950)	(22,667)	(27,487)	(31,425)
Other Operating Profit (13,318) (2,956) (22,859) (27,008) (33,188) (33,181) (23,565) (22,859) (27,408) (33,181) (33,181) (20,509) (27,407) (31,426) (31,426) (31,426) (31,426) (31,426) (31,426) (31,426) (31,426) (31,426) (31,427) (31,426)	Intangible Amortization		25		77	78	79	80
Operating Profit (13.318) (9.396) (21.866) (22.589) (27.408) (31.34 Net Interest) (3.360) (9.224) (21.816) (22.590) (27.487) (31.42 Pre-tax Profit (fropmote) (13.266) (9.224) (21.816) (22.590) (27.487) (31.42 Pre-tax Profit (fropmote) (13.266) (9.224) (21.816) (22.590) (27.487) (31.43 Rax (31) (3	Exceptionals		0	(15)	17	0	0	C
Net Interest Net I	Other			0	0		0	C
Pre-lax Profit (norm) (13,260) (2,24) (21,816) (22,590) (27,887) (31,42) Per-lax Profit (reported) (13,258) (9,191) (21,721) (22,513) (27,608) (31,34) fax (31) (31) (31) (31) (31) (31) (31) (31)	Operating Profit		(13,318)		(21,856)	(22,589)	(27,408)	(31,345)
Pro-Lax Profit (regorded)	Net Interest						0	0
Tax	Pre-tax Profit (norm)		(13,260)	(9,224)	(21,816)	(22,590)	(27,487)	(31,425)
Profit After Tax (norm)	Pre-tax Profit (reported)					(22,513)		(31,345)
Profit After Tax (reported) (13.266) (9.222) (21,753) (22,544) (27,440) (31,37] Average Number of Shares Outstanding (m) 23.2 30.8 32.4 32.4 32.4 32.4 32.4 32.2 52.64 (10.57) (10.30) (10.67) (10.70) (10.68) (10.57) (10.57) (10.30) (10.67) (10.70) (10.68) (10.57) (10.57) (10.30) (10.67) (10.70) (10.68) (10.57)	Tax						(31)	(31)
Average Number of Shares Outstanding (m) 23.2 30.8 32.4 32.4 32.4 32.4 32.4 32.4 32.4 32.4	Profit After Tax (norm)							(31,457)
Average number of ADS outslanding (m) PEADR - normalized (s) PEADR - normalized and fully diluted (s) PEADR - (reported) (s) PEADR - reported (s) PEADR - salt salt salt salt salt salt salt salt	Profit After Tax (reported)		(13,266)	(9,222)	(21,753)	(22,544)	(27,440)	(31,376)
Average number of ADS outslanding (m) PEADR - normalized (s) PEADR - normalized and fully diluted (s) PEADR - (reported) (s) PEADR - reported (s) PEADR - salt salt salt salt salt salt salt salt	Average Number of Shares Outstanding (m)		23.2	30.8	32.4	32.4	32.4	32.4
EPADR - normalized (s) (0.57) (0.30) (0.67) (0.70) (0.85) (0.95) (0.								32.4
EPADR - (reported) (\$) (0.57) (0.30) (0.67) (0.70) (0.85) (0.95) (0.	EPADR - normalized (\$)							(0.97)
EPADR (reported) (\$) (0.57) (0.30) (0.67) (0.70) (0.85) (0.90) (0.00								(0.97)
Divident per share (\$)								(0.97)
Gross Margin (%) 20.8 26.9 30.2 32.3 29.6 29 EBITDA Margin (%) .105.0 .58.0 .136.6 .139.7 .143.9 .129 Operating Margin (before GW and except.) (%) .105.4 .58.4 .137.4 .140.6 .145.2 .131 BALANCE SHET Fixed Assets 438 1,353 1,302 1.975 2,598 3,33 Intangible Assets 64 546 430 412 2,598 3,33 Investments 302 402 434 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.0</td></td<>								0.0
EBITDA Margin (%) 105.0 58.0 136.6 139.7 143.9 1.29	· · · · · · · · · · · · · · · · · · ·							
Departing Margin (before GW and except.) (%) -105.4 -58.4 -137.4 -140.6 -145.2 -131								
Page								
Fixed Assets	1 0 0 1		100.4	30.4	137.4	140.0	140.2	131.2
Intangible Assets 64 546 430 412 343 22 23 23 23 23 23			400	4.050	4 000	4.075	0.500	0.007
Tangible Assets 71 405 438 1,129 1,821 2,66 Investments 302 402 434 436 186 186 180 17,68 180 181,68 180 180 17,68 180 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>								
Investments 302 402 434 444 434 44								273
Current Assets 63,091 60,249 39,891 19,618 16,803 17,66 Stocks 1,034 2,021 1,099 1,869 2,282 2,88 Debtors 0 2,253 2,485 884 1,037 1,33 Cash 43,753 42,083 35,218 15,778 12,397 12,33 Other 18,304 13,891 1,087 1,083 0 23,538 (54,79 0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								
Stocks 1,034 2,021 1,099 1,869 2,282 2,80 Debtors 0 2,253 2,485 884 1,037 1,37 Cash 43,753 42,083 35,218 15,778 12,397 12,37 Chirer 18,304 13,891 1,087 1,087 1,087 1,087 1,087 Current Liabilities (2,074) (4,033) (4,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553) (6,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553) (6,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553) (6,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553) (4,553) (6,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553) (4,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553								
Debtors 0 2,253 2,485 884 1,037 1,3 Cash 43,753 42,083 35,218 15,778 12,397 12,38 Other 18,304 1,3891 1,087 0,083 0 0 0 0 0 0 0								
Cash 43,753 42,083 35,218 15,778 12,397 12,397 Other 18,304 13,891 1,087 1,088 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 23,558 (54,81 1,679 0 0 0								
Other 18,304 13,891 1,087 1,083 1,083 1,083 1,083 1,083 1,083 1,083 1,083 1,083 1,083 1,083 1,083 1,047 1,047 1,047 1,047 1,047 1,047 1,047 1,047 1,047 1,047 1,047 1,047 <								
Current Liabilities (2,074) (4,033) (4,553) (6,553) (7,412) (8,30) Creditors (2,074) (4,033) (4,553) (6,553) (7,412) (8,30) Short term borrowings 0 0 0 0 0 0 Long term borrowings 0 0 0 0 0 23,538) (54,79) Other long term liabilities (25) (19) (13) (18) (18) (1 Net Assets 61,430 57,550 36,626 15,022 (11,567) (42,09) CASH FLOW Operating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01 Net Interest 55 222 146 92 0 Tax (31)								
Creditors (2,074) (4,033) (4,553) (6,553) (7,412) (8,30) Short term borrowings 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 23,556) (54,81 1								
Short term borrowings 0 0 0 0 0 Long Term Liabilities (25) (19) (13) (18) (23,556) (54,81 Long term borrowings 0 0 0 0 0 (23,538) (54,79 Other long term liabilities (25) (19) (13) (18) (18) (1 Net Assets 61,430 57,550 36,626 15,022 (11,567) (42,09 CASH FLOW (31) (30,01 (30,								
Long Term Liabilities (25) (19) (13) (18) (23,556) (54,81) Long term borrowings 0 0 0 0 0 (23,538) (54,79) Other long term liabilities (25) (19) (13) (18) (18) (1 Net Assets 61,430 57,550 36,626 15,022 (11,567) (42,09 CASH FLOW Operating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01 Net Interest 55 222 146 92 0 Tax (31) (31) (31) (31) (31) (31) (31) (31) (31) (32) (3								(6,303)
Long term borrowings 0 0 0 0 2,538 (54,79 Other long term liabilities (25) (19) (13) (18) (18) (1 Net Assets 61,430 57,550 36,626 15,022 (11,567) (42,09 CASH FLOW Operating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01 Net Interest 55 222 146 92 0 Tax (31) (3								
Other long term liabilities (25) (19) (13) (18) (18) (1 Net Assets 61,430 57,550 36,626 15,022 (11,567) (42,09 CASH FLOW Operating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01 Net Interest 55 222 146 92 0 Tax (31)			, ,	. ,	. ,	. ,		
Net Assets 61,430 57,550 36,626 15,022 (11,567) (42,09) CASH FLOW Upgerating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01) Net Interest 55 222 146 92 0 Tax (31) <td< td=""><td><u> </u></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td>(18)</td></td<>	<u> </u>			-				(18)
CASH FLOW Operating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01) Net Interest 55 222 146 92 0 Tax (31) <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>. , ,</td><td></td></td<>							. , ,	
Operating Cash Flow (13,886) (10,655) (18,889) (18,684) (25,932) (30,01) Net Interest 55 222 146 92 0 Tax (31)			01,430	37,330	30,020	13,022	(11,507)	(42,073)
Net Interest 55 222 146 92 0 Tax (31)			(40.00()	(40 (55)	(40,000)	(10 (04)	(05.000)	(00.045)
Tax (31)					,			
Capex 0 (368) (186) (806) (946) (1,19 Acquisitions/disposals 0 13,25 0 0 0 0 0 0 0 0 0 0 15,778 11,14 0								(01)
Acquisitions/disposals 0								(31)
Financing 33,533 4,500 (15) 0 0 Dividends 0 0 0 0 0 0 Net Cash Flow 8,712 (1,670) (6,865) (19,440) (26,920) (31,25 Opening net debt/(cash) (35,042) (43,753) (42,083) (35,218) (15,778) 11,14 HP finance leases initiated 0 0 0 0 0 Other 0 (0) (0) 0 0 0								
Dividends 0 0 0 0 0 0 Net Cash Flow 8,712 (1,670) (6,865) (19,440) (26,920) (31,25 Opening net debt/(cash) (35,042) (43,753) (42,083) (35,218) (15,778) 11,14 HP finance leases initiated 0 0 0 0 0 0 Other 0 (0) (0) (0) 0 0	_ ·							0
Net Cash Flow 8,712 (1,670) (6,865) (19,440) (26,920) (31,25 Opening net debt/(cash) (35,042) (43,753) (42,083) (35,218) (15,778) 11,14 HP finance leases initiated 0 0 0 0 0 Other 0 (0) (0) 0 0								0
Opening net debt/(cash) (35,042) (43,753) (42,083) (35,218) (15,778) 11,14 HP finance leases initiated 0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(21.254)</td></t<>								(21.254)
HP finance leases initiated 0 0 0 0 0 Other 0 (0) (0) 0 0								
Other 0 (0) (0) 0 0				,	,			11,141
								0
Gushiy net ueuv(cash) (35,218) (15,778) 11,141 42,3°								42.205
	Ciosing het debi/(cash)		(43,/53)	(42,083)	(35,218)	(15,778)	11,141	42,395

Source: SymBio accounts, Edison Investment Research. Note: Our 2017-18 long-term liabilities include illustrative financing of c \pm 6.6bn (\$55m), which we classify as a long-term liability for the purposes of our model. Solely for the convenience of the reader the financial summary table has been converted at a rate of \pm 121/US\$. SymBio reports statutory accounts in Japanese yen. These translations should not be considered representations that any such amounts have been or could be converted into US dollars at the assumed conversion rate.



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by SymBio Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report per represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distincted in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report. well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainlies and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law. Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (*FTSE*) * FTSE 2016. *FTSE* is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE rating or underlying data. No further distribution of FTSE bala is permitted without FTSE's express written consent.